26137-07-5Relevant articles and documents
β-Selective C?H Arylation of Electron-Deficient Thiophenes, Pyrroles, and Furans
Liu, Luo-Yan,Qiao, Jennifer X.,Ewing, William R.,Yeung, Kap-Sun,Yu, Jin-Quan
, p. 416 - 418 (2020/02/20)
A general β-C?H arylation of electron-deficient thiophenes, pyrroles, and furans has been developed using ligand-modulated palladium catalyst. The use of a modified norbornene is crucial for reversing the conventional α-selectivity of these substrates. This method features good yields, high β-selectivity, and good tolerance of functional groups.
THIOPHENE AMINO ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
-
Page/Page column 30, (2008/06/13)
Compounds of formula (I), in which: R1 and R2, which may be identical or different, independently of each other, each represent a group selected from: hydrogen, halogen, cyano, nitro, halo(C1-C6)alkyl, halo(Csu
5-FLUORO-THIOPEN-COMPOUNDS,THE PROCESS FOR THEIR PREPARATION,THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS METALLOPOTENASES INHIBITORS
-
Page 21-22, (2008/06/13)
Compounds of formula (I) in which R1 represent a group selected from halo(C1-C6)alkoxy, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, phenyl, cyclohexyl an
The application of vinamidinium salts to the synthesis of 2,4-disubstituted thiophenes
Clemens, Ryan T.,Smith, Stanton Q.
, p. 1319 - 1320 (2007/10/03)
The synthesis of 2,4-disubstituted thiophenes by the condensation of symmetrical vinamidinium salts with methyl thioglycolate has been accomplished for the first time. Simple experimental conditions were used to prepare seven different methyl 4-aryl-2-thi
Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them
-
Page/Page column 43, (2010/11/30)
A compound of formula (I) selected from: wherein: X represents oxygen or sulphur, Y represents oxygen, —NH— or —N(C1-C6)alkyl-, Ra represents hydrogen, halogen, (C1-C3)alkyl, hydroxyl or (C1-C3)alkoxy, Rb represents hydrogen, halogen or (C1-C3)alkyl, A represents phenyl, pyridyl, (C5-C6)cycloalkyl or (C5-C6)cycloalkenyl, R1 and R2 each represent a group selected from hydrogen, halogen, cyano, nitro, haloalkyl, haloalkoxy, alkyl, alkenyl, alkynyl, —OR4, —NR4R5, —S(O)nR4, —C(O)R4, —CO2R4, —O—C(O)R4, —C(O)NR4R5, —NR5—C(O)R4, —NR5—SO2R4, -T-CN, -T-OR4, -T-OCF3, -T- NR4R5, -T-S(O)nR4, -T-C(O)R4, -T-CO2R4, -T-O—C(O)R4, -T-C(O)NR4R5, -T-NR4—C(O)R5, -T-NR4—SO2R5, —R6 and -T-R6 in which n, T, R4, R5 and R6 are as defined in the description, R3 represents an —R7 or —U—R11 group in which R7 represents hydrogen, alkyl, aryl, cycloalkyl or heterocycle, U represents a linear or branched alkylene chain and R11 is defined in the description, their optical isomers or their addition salts with a pharmaceutically acceptable acid or base, and their use as inhibitor of metalloproteinase and more specifically of metalloproteinase-12.